Progression of liver oncogenesis in the double transgenic mice c-myc/TGF α is not enhanced by cyclooxygenase-2 expression

Llorente, Cristina; Mayoral, Rafael; Cucarella, Carme; Grau, Carlos; Alvarez, María Soledad; Flores, Juana M.; García-Palencia, Pilar; Agra, Noelia; Castro-Sánchez, Luis; Martı́n-Sanz, Paloma; Casado, Marta

doi:10.1016/j.prostaglandins.2013.03.006

Cited by 4 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, work from our group[51] has shown that COX-2 expression is not sufficient to exacerbate malignant transformation after administration of chemical hepatocarcinogens. Even more, progression of liver oncogenesis in a well-established model of HCC (the c-myc and TGF-α double transgenic mice), is not affected by COX-2 expression[52]. However, COX-2 expression in this model facilitated the development of preneoplastic foci but failed to promote malignant transformation, probably as result of the contribution of COX-2-derived PGs to inhibit apoptosis and to provide an anti-inflammatory environment, these conditions opposing the initiation of the early phases of HCC.…”

Section: Cox-2 and Hccmentioning

confidence: 99%

Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives

Martı́n-Sanz

Casado

2017

WJG

Self Cite

View full text Add to dashboard Cite

The biosynthesis of prostaglandins and thromboxanes has been a focus of interest in the management of many liver diseases. Cyclooxygenases are the enzymes involved in the first step of the biosynthesis of these lipid mediators and selective inhibitors for these isoenzymes as well as pharmacological analogues of prostaglandins have been developed and are currently applied therapeutically. Here we discuss the implications of these enzymes in the onset of metabolic and lipid disorders in the liver and their potential role in the progression of the diseases towards fibrosis and hepatocellular carcinogenesis.

show abstract

Section: Cox-2 and Hccmentioning

confidence: 99%

Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives

Martı́n-Sanz

Casado

2017

WJG

Self Cite

View full text Add to dashboard Cite

show abstract

“… 46 On the other hand, other studies reported that transgenic mice expressing COX-2 in hepatocytes revealed a minor contribution to other HCC mouse models, such as chemical diethylnitrosamine (DEN) and other genetic mouse models. 47 , 48 Therefore, the role of COX-2 in HCC may be more complex and context-dependent. Additional research will be necessary to fully elucidate the role of COX-2 in HCC and to develop effective therapeutic strategies targeting this pathway.…”

Section: Microbial-associated Molecular Patterns (Mamps) and Pathogen...mentioning

confidence: 99%

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond

Ohtani,

Kamiya,

Kawada

2023

Hepatology Communications

View full text Add to dashboard Cite

The gut and the liver are anatomically and physiologically connected, and this connection is called the “gut-liver axis,” which exerts various influences on liver physiology and pathology. The gut microbiota has been recognized to trigger innate immunity and modulate the liver immune microenvironment. Gut microbiota influences the physiological processes in the host, such as metabolism, by acting on various signaling receptors and transcription factors through their metabolites and related molecules. The gut microbiota has also been increasingly recognized to modulate the efficacy of immune checkpoint inhibitors. In this review, we discuss recent updates on gut microbiota-associated mechanisms in the pathogenesis of chronic liver diseases such as NAFLD and NASH, as well as liver cancer, in light of the gut-liver axis. We particularly focus on gut microbial metabolites and components that are associated with these liver diseases. We also discuss the role of gut microbiota in modulating the response to immunotherapy in liver diseases.

show abstract

“…out YAP/TAZ[31].Xu et al found that YAP played an important role in COX-2-induced carcinogenesis in HCC through activation of the Wnt/β-catenin pathway…”

mentioning

confidence: 99%

Expression of cyclo-oxygenase-2 and yap/taz in hepatocellular carcinoma in untreated and treated hepatitis C virus patients

Sweed¹,

Abd-Elbary²,

Sweed³

et al. 2022

pjp

View full text Add to dashboard Cite

The pathogenesis of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) differs according to whether prior treatment with interferon (IFN) vs. direct-acting antiviral agents (DAAs) was administered. Cyclooxygenase-2 (COX-2), yes-associated protein 1 (YAP), and transcriptional co-activator with PDZ-binding motif (TAZ) play a crucial role in hepatocarcinogenesis. However, their roles in untreated or treated HCV-related HCC development have not been clarified. Therefore, we performed an immunohistochemical study and stained tissue from 83 HCV-related HCC cases using antibodies against COX-2, YAP, and TAZ and correlated their expression with the clinicopathological characteri stics and survival data. The cases were subdivided into 3 groups based on prior HCV treatment. In the 3 groups, COX-2 was significantly higher in HCC tissue compared with adjacent non-tumour liver tissue. However, the expression of YAP/TAZ was not significantly different between HCC and adjacent non-tumour tissue. We further grouped HCC cases into YAP + /TAZ + and YAP -/TAZcases. In the YAP + /TAZ + cases, COX-2 was significantly associated with tumour size, tumour multifocality, and late pathologic stage. No significant difference was observed in COX-2 and TAZ expression as a result of IFN or DAA treatment; however, YAP was significantly higher in IFN-treated HCC. Cyclo-oxygenase-2 overexpression may play a role in late HCC development, while YAP/TAZ could play an early role in HCC progression. Sustained expression of combined YAP/TAZ could mediate the poor prognostic role of COX-2.

show abstract

Progression of liver oncogenesis in the double transgenic mice c-myc/TGF α is not enhanced by cyclooxygenase-2 expression

Cited by 4 publications

References 37 publications

Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives

Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond

Expression of cyclo-oxygenase-2 and yap/taz in hepatocellular carcinoma in untreated and treated hepatitis C virus patients

Contact Info

Product

Resources

About